This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making health decisions based on this content.
By HathawayMD.com Editorial Team | Last verified: August 2026
In This Article
- What Vitamin K2 (Menaquinone) Is
- How Vitamin K2 (Menaquinone) Works in Your Body
- What the Research Shows About Vitamin K2
- Forms and Bioavailability of Vitamin K2
- Who Should Consider Vitamin K2 and Who Should Avoid It
- Safety, Side Effects, and Drug Interactions with Vitamin K2
- Key Takeaway: Vitamin K2 (Menaquinone) Bottom Line
What Vitamin K2 (Menaquinone) Is
Vitamin K2, also called menaquinone, is a fat-soluble vitamin produced primarily by bacteria in the gut and in fermented foods. Unlike Vitamin K1 (phylloquinone)—which comes from leafy greens and is mainly used in blood clotting—Vitamin K2 functions in a different metabolic pathway: it activates specific proteins involved in bone mineralization and cardiovascular regulation.
Vitamin K2 exists in multiple forms, called homologs, based on the length of their side chains. The most studied forms are MK-7 (menaquinone-7), which comes from fermented foods like natto (fermented soybeans) and some cheeses, and MK-4 (menaquinone-4), which is produced in small amounts by animal tissues and can be synthesized in the laboratory. Each form has different absorption and tissue distribution patterns.
Natural dietary sources include:
- Natto (fermented soybeans) — highest concentration, ~100–200 mcg per 100g
- Hard and soft cheeses — 10–75 mcg per serving, depending on type
- Fermented dairy products like kefir and yogurt
- Sauerkraut and other fermented vegetables
- Grass-fed animal products (meat, dairy, eggs) in small amounts
- Bacterial production in the colon (variable and not reliably absorbed)
Most Western diets are low in Vitamin K2 because fermented foods are not staples, and modern food processing reduces bacterial fermentation that produces it naturally.
How Vitamin K2 (Menaquinone) Works in Your Body
Vitamin K2 acts as a biological cofactor—a helper molecule—that activates a family of proteins called Gla proteins (gamma-carboxyglutamic acid proteins). These proteins require Vitamin K2 to function properly. Two key Gla proteins are:
Osteocalcin (bone health): Produced by osteoblasts (bone-building cells), osteocalcin binds mineral (calcium and phosphate) to the bone matrix. Without sufficient K2 activation, osteocalcin cannot perform this function effectively, potentially weakening bone structure.
Matrix Gla Protein (cardiovascular regulation): Found in vascular smooth muscle and the extracellular matrix, this protein inhibits calcium deposition in soft tissues (arteries and tendons). K2 activation helps direct calcium away from vessels and toward bone where it belongs.
The activation process requires K2 to be converted into its active form (hydroquinone) by cellular enzymes. This is why K2 must be taken with dietary fat—the fat enhances absorption in the small intestine. Once absorbed, K2 is stored in the liver and other organs for weeks, allowing for less frequent dosing than some water-soluble vitamins.
What the Research Shows About Vitamin K2
Bone Health — Moderate Evidence
Several randomized controlled trials (RCTs) have examined K2's effect on bone mineral density and fracture risk. A 2013 meta-analysis in *Osteoporosis International* reviewed 13 studies and found that MK-7 supplementation was associated with modest improvements in bone mineral density at the lumbar spine and hip, though the effect size was small (mean difference ~1–2%). Doses studied ranged from 45–180 mcg daily over 1–3 years.
In postmenopausal women, one 2015 Japanese RCT (180 participants) found that 180 mcg daily of MK-7 over 6 months slowed bone loss compared to placebo. However, studies on fracture prevention itself (the most clinically relevant outcome) remain limited. Most evidence is considered moderate rather than strong because study sizes have been modest and follow-up periods relatively short.
Cardiovascular Health — Preliminary to Moderate Evidence
Observational studies suggest that higher K2 intake is associated with lower cardiovascular disease risk and less arterial calcification. A 2015 study in *Thrombosis and Haemostasis* (Rotterdam study, 4,800 participants) found that dietary K2 intake was inversely related to coronary calcification—higher K2 intake correlated with less calcium buildup in arteries. However, this was an observational study, meaning causation cannot be proven.
RCTs specifically testing K2 supplementation for cardiovascular outcomes remain scarce. Most evidence is mechanistic (showing how it *should* work) rather than outcome-based. No large cardiovascular event trials have been completed yet.
Vascular Stiffness — Preliminary Evidence
A 2015 study in *Nutrition, Metabolism and Cardiovascular Diseases* found that 180 mcg MK-7 daily for 12 weeks improved arterial flexibility in healthy postmenopausal women. However, sample size was small (68 participants) and long-term clinical significance remains unclear.
Key evidence grades: Bone health = Moderate; cardiovascular = Preliminary to Moderate; fracture prevention = Insufficient (limited RCT data).
Forms and Bioavailability of Vitamin K2
MK-7 (Menaquinone-7): Derived from natto or synthesized by bacterial fermentation. Has a longer side chain and a longer half-life (~2.5–3 days) than other forms, meaning it circulates longer and accumulates in tissues more readily. Better absorption with dietary fat. Requires less frequent dosing. Most research on supplementation uses MK-7.
MK-4 (Menaquinone-4): Shorter side chain; found naturally in small amounts in animal products. Shorter half-life (~1 hour). Requires higher doses to maintain steady-state levels. Often requires multiple daily doses. Historically studied in Japanese bone health research.
Absorption matters: K2 is fat-soluble and requires dietary fat for optimal absorption. Taking K2 with a meal containing 5–10 grams of fat (nuts, olive oil, avocado, etc.) increases blood levels significantly compared to taking it fasting. Supplements are often available as softgels in oil to address this.
Bioavailability also depends on gut health. Those with malabsorption disorders (celiac disease, cystic fibrosis, inflammatory bowel disease) may have reduced K2 absorption and could benefit from higher doses, though this should be individualized with a healthcare provider.
Who Should Consider Vitamin K2 and Who Should Avoid It
Consider supplementation if you:
- Have low dietary intake of fermented foods and grass-fed dairy (most Western diets qualify)
- Have postmenopausal osteopenia or osteoporosis and want to explore adjunctive strategies
- Have concerns about arterial calcification or cardiovascular health
- Are unable to meet K2 needs through diet alone due to food preferences or restrictions
Avoid or use with caution if you:
- Take warfarin (Coumadin) or other anticoagulants — K2 can reduce anticoagulant effectiveness. Consult your prescriber before supplementing.
- Have a history of blood clots or thrombosis — K2's role in coagulation regulation warrants medical supervision
- Have severe liver disease — the liver stores and metabolizes K2
- Are pregnant — evidence on K2 supplementation in pregnancy is insufficient; dietary sources are preferred
Safety, Side Effects, and Drug Interactions with Vitamin K2
Side effects: At doses used in research (typically 45–180 mcg daily), Vitamin K2 is generally well-tolerated with no serious adverse effects reported in clinical trials. A few participants have reported mild gastrointestinal upset (nausea, constipation), but these are rare and not dose-dependent in most studies.
No established upper limit (UL) exists for Vitamin K2 because toxicity from high intakes has not been documented. However, this does not mean unlimited amounts are safe—research on very high doses (>1,000 mcg daily) is limited.
Drug interactions:
- Anticoagulants (warfarin, acenocoumarol): K2 may antagonize anticoagulant effect, increasing clot risk. Close INR monitoring is needed if starting or changing K2 intake. Direct oral anticoagulants (DOACs like apixaban) have less interaction but still warrant caution.
- Antibiotics: Broad-spectrum antibiotics may reduce gut bacterial production of K2, but dietary supplements are not affected.
- Fat-malabsorption medications: Drugs that reduce fat absorption (orlistat, bile acid sequestrants) may impair K2 absorption.
Key Takeaway: Vitamin K2 (Menaquinone) Bottom Line
Vitamin K2 is a fat-soluble vitamin with a plausible role in bone mineralization and cardiovascular regulation through activation of specific Gla proteins. Evidence for bone health is moderate, supported by several RCTs showing modest improvements in bone mineral density. Evidence for cardiovascular benefit remains preliminary—mechanistically sound but lacking large-scale clinical trials on hard outcomes.
For most people, K2 is safe and well-tolerated at supplement doses of 45–180 mcg daily, particularly MK-7 forms. The most significant limitation is the interaction with anticoagulants, which requires medical oversight. A more practical first step for many is to increase dietary K2 through fermented foods and quality dairy rather than rely solely on supplements, though supplementation may be reasonable for those with low dietary intake or specific health concerns.
Research is ongoing, and clinical practice continues to evolve. If you're considering K2 supplementation, involve your healthcare provider—especially if you take blood thinners or have bone or cardiovascular concerns.
Leave a Reply
You must be logged in to post a comment.